Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced that its President and CEO, Richard Francis, will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation is scheduled to begin at 11:30 A.M. Eastern Time.
Interested parties can access a live webcast of the presentation through Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. For those unable to attend the live event, an archived version of the webcast will be made available within 24 hours after the conclusion of the live discussion.
Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato che il suo Presidente e CEO, Richard Francis, parteciperà alla 22ª Conferenza Sanitaria Globale Annuale di Morgan Stanley mercoledì, 4 settembre 2024. La presentazione è programmata per iniziare alle 11:30 A.M. Ora Orientale.
Le parti interessate possono accedere a un webcast in diretta della presentazione attraverso il sito web delle Relazioni con gli Investitori di Teva all'indirizzo https://ir.tevapharm.com/Events-and-Presentations. Per coloro che non possono partecipare all'evento dal vivo, una versione archiviata del webcast sarà disponibile entro 24 ore dopo la conclusione della discussione dal vivo.
Teva Pharmaceutical Industries (NYSE y TASE: TEVA) ha anunciado que su Presidente y CEO, Richard Francis, presentará en la 22ª Conferencia Anual Global de Salud de Morgan Stanley el miércoles 4 de septiembre de 2024. La presentación está programada para comenzar a las 11:30 A.M. Hora del Este.
Las partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web de Relaciones con Inversores de Teva en https://ir.tevapharm.com/Events-and-Presentations. Para aquellos que no puedan asistir al evento en vivo, se pondrá a disposición una versión archivada del webcast dentro de las 24 horas posteriores a la conclusión de la discusión en vivo.
테바 제약 산업 (NYSE 및 TASE: TEVA)이 회장 겸 CEO 리차드 프랜시스가 모건 스탠리 제22회 세계 의료 콘퍼런스에서 발표할 것이라고 발표했습니다. 발표는 2024년 9월 4일 수요일 오전 11:30 동부 표준시에 시작될 예정입니다.
관심 있는 당사자는 Teva의 투자자 관계 웹사이트를 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다: https://ir.tevapharm.com/Events-and-Presentations. 실시간 행사에 참석할 수 없는 분들을 위해, 보관된 버전의 웹캐스트는 실시간 토론이 끝난 후 24시간 이내에 제공됩니다.
Teva Pharmaceutical Industries (NYSE et TASE : TEVA) a annoncé que son Président et CEO, Richard Francis, interviendra lors de la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le mercredi 4 septembre 2024. La présentation est prévue pour commencer à 11h30, Heure de l'Est.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site Web des Relations Investisseurs de Teva à l'adresse https://ir.tevapharm.com/Events-and-Presentations. Pour ceux qui ne peuvent pas assister à l'événement en direct, une version archivée du webinaire sera disponible dans les 24 heures suivant la fin de la discussion en direct.
Teva Pharmaceutical Industries (NYSE und TASE: TEVA) hat angekündigt, dass sein Präsident und CEO, Richard Francis, auf der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley am Mittwoch, den 4. September 2024, präsentieren wird. Die Präsentation ist für 11:30 Uhr Eastern Time geplant.
Interessierte Parteien können über die Website der Investor Relations von Teva unter https://ir.tevapharm.com/Events-and-Presentations auf einen Live-Webcast der Präsentation zugreifen. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird innerhalb von 24 Stunden nach Abschluss der Live-Diskussion eine archivierte Version des Webcasts zur Verfügung gestellt.
- None.
- None.
TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time.
To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; our substantial indebtedness; our business and operations in general including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| IR Contacts | Ran Meir | +1 (215) 591-8912 |
| Yael Ashman | +972 (3) 914 8262 | |
| Sanjeev Sharma | +1 (973) 658 2700 | |
| PR Contacts | Kelley Dougherty | +1 (973) 832-2810 |
| Eden Klein | +972 (3) 906 2645 |
FAQ
When is Teva Pharmaceutical (TEVA) presenting at the Morgan Stanley Healthcare Conference in 2024?
Who will be representing Teva Pharmaceutical (TEVA) at the Morgan Stanley Healthcare Conference?
How can I watch Teva Pharmaceutical's (TEVA) presentation at the Morgan Stanley Healthcare Conference?
Will there be a replay available of Teva Pharmaceutical's (TEVA) presentation at the Morgan Stanley Healthcare Conference?
